AI
Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Bridgene Biosciences Announces $12 Million Series A Financing To Advance The Company'S Proprietary Chemoproteomic Platform And Pipeline Of Oncology Programs
Bridgene Biosciences Announces $12 Million Series A Financing To Advance The Company'S Proprietary Chemoproteomic Platform And Pipeline Of Oncology Programs
05/05/21, 11:46 AM
Location
sunnyvale
Money raised
$12 million
Round Type
series a
BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undruggable targets, announced today it has raised $12 million in a Series A private financing round led by Wedo Venture Partners with additional participation by Kaitai Capital and Takeda Ventures, alongside existing investor Pangu Venture.
Company Info
Location
sunnyvale, california, united states
Additional Info
BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat diseases. By utilizing its proprietary chemoproteomic platform IMTACTM, BridGene is able to screen small molecules against all proteins in live cells to discover drug candidates for high value, yet hard-to-drug targets. The ultimate goal is to enable breakthrough small-molecule drug discovery and to expand the mechanisms to treat diseases, with targets previously inaccessible to small molecules. The company is advancing a diversified pipeline of first-in-class drugs for targets in multiple disease areas. For more information, visit http://bridgenebio.com
ContactTiberend Strategic Advisors, Inc.Miriam Weber Miller (investors)212-375-2694[email protected]
Johanna Bennett (media)212-375-2686[email protected]
SOURCE BridGene Biosciences
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.